H. Lundbeck A/S

CPSE:HLUN B Rapport sur les actions

Capitalisation boursière : DKK 40.5b

H. Lundbeck Croissance future

Future contrôle des critères 0/6

Le chiffre d'affaires et le bénéfice de H. Lundbeck devraient diminuer respectivement de 3.4% et de 4.5% par an. Le BPA devrait diminuer de 3.7% par an. Le rendement des capitaux propres devrait être de 13.3% dans 3 ans.

Informations clés

-4.5%

Taux de croissance des bénéfices

-3.73%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices10.7%
Taux de croissance des recettes-3.4%
Rendement futur des capitaux propres13.26%
Couverture par les analystes

Good

Dernière mise à jour18 Jun 2026

Mises à jour récentes de la croissance future

Article d’analyse • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Article d’analyse • Feb 07

H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...
Article d’analyse • Nov 15

Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...
Article d’analyse • Aug 16

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...

Recent updates

Article d’analyse • Jun 18

H. Lundbeck (CPSE:HLUN B) Stock Could Be 10% Undervalued After Asedebart Phase II Data

H. Lundbeck (CPSE:HLUN B) stock is in focus after the company reported preliminary Phase II Part A data for asedebart in Cushing's disease, showing urinary free cortisol normalization in most evaluable patients. See our latest analysis for H. Lundbeck. The preliminary asedebart data arrives after a steady run in H. Lundbeck's stock, with the latest share price at DKK42.32, a 30 day share price return of 5.43% and a 90 day share price return of 13.95%, while the 1 year total shareholder return...
Mise à jour du récit • Jun 06

HLUN B: Softer Revenue Outlook Will Weigh On Future Earnings Multiple

Analysts now keep their DKK 34.00 price target for H. Lundbeck unchanged, citing a slightly higher assumed discount rate, softer revenue growth, and firmer profit margin and future P/E expectations in their models.
Article d’analyse • May 24

H. Lundbeck's (CPH:HLUN B) Solid Earnings Have Been Accounted For Conservatively

H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...
Mise à jour du récit • May 23

HLUN B: Neuroscience Pipeline Progress And Dividend Policy Will Support Future Upside

Analysts now estimate fair value for H. Lundbeck at about DKK47.21 per share, up from roughly DKK46.13.
Article d’analyse • May 15

Earnings Beat: H. Lundbeck A/S Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

H. Lundbeck A/S ( CPH:HLUN B ) just released its latest quarterly results and things are looking bullish. H. Lundbeck...
Mise à jour du récit • May 05

HLUN B: Late-Stage Neurology Pipeline Will Support Future Margins

Analysts have nudged their fair value estimate for H. Lundbeck stock from DKK 61.99 to DKK 63.32, reflecting updated views on revenue growth, profit margins and future P/E assumptions.
Mise à jour du récit • Apr 20

HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook

Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.
Mise à jour du récit • Apr 05

HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins

Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.
Mise à jour du récit • Mar 22

HLUN B: Neurology Pipeline Progress Will Support Future Margin Expansion

Analysts have reduced their price target on H. Lundbeck to DKK 61.99 from DKK 66.52, reflecting updated assumptions for slightly softer revenue growth, profit margins, and a lower future P/E multiple.
Mise à jour du récit • Mar 08

HLUN B: Migraine Pipeline Progress Will Support Constructive Medium Term Upside Potential

Analysts have raised their H. Lundbeck price target from DKK 44.95 to DKK 46.13, citing updated assumptions around revenue growth, profit margins and future P/E as the main factors behind the change.
Mise à jour du récit • Feb 22

HLUN B: Positive Neuroscience Pipeline Data Will Support Constructive Medium Term Outlook

Analysts have trimmed their DKK price target on H. Lundbeck from about DKK 47.05 to DKK 44.95, citing updated assumptions for revenue growth, profit margins, as well as a slightly higher future P/E multiple and discount rate.
Mise à jour du récit • Feb 08

HLUN B: Weaker Long Term Revenue And Margin Outlook Will Pressure Shares

Analysts have reduced their price target on H. Lundbeck from €39.00 to €34.00, citing updated assumptions for revenue growth, profit margins, and a slightly higher discount rate, while keeping the forward P/E outlook broadly similar.
Article d’analyse • Feb 07

H. Lundbeck A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

It's been a sad week for H. Lundbeck A/S ( CPH:HLUN B ), who've watched their investment drop 11% to kr.37.46 in the...
Mise à jour du récit • Jan 25

HLUN B: Pipeline And Guidance Updates Will Support Balanced Medium Term Outlook

Analysts have lifted their price target for H. Lundbeck from €45.55 to about €47.05, reflecting updated assumptions that include slightly lower revenue growth, a higher profit margin and a marginally adjusted forward P/E multiple.
Article d’analyse • Jan 14

H. Lundbeck (CPH:HLUN B) Seems To Use Debt Rather Sparingly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Mise à jour du récit • Jan 11

HLUN B: Pipeline Progress And Partnerships Will Support Balanced Medium Term Outlook

Analysts have trimmed their price target for H. Lundbeck to €45.55 from €48.18, reflecting updated views on slightly softer revenue growth assumptions, a modestly higher discount rate, a small uplift in expected profit margins, and a lower future P/E multiple.
Mise à jour du récit • Dec 27

HLUN B Will Benefit From Expanding Neurology Pipeline And Margin Improvements

Narrative Update on H. Lundbeck Analysts have modestly increased their price target on H.
Mise à jour du récit • Dec 13

HLUN B: Long Term Revenue Outlook Will Likely Weigh On Shares

Analysts have nudged their price target on H. Lundbeck up by approximately 1 currency unit to 39, citing a slightly higher projected profit margin and modestly richer future valuation multiples, even as they temper long term revenue growth expectations and apply a marginally higher discount rate.
Article d’analyse • Nov 22

The Strong Earnings Posted By H. Lundbeck (CPH:HLUN B) Are A Good Indication Of The Strength Of The Business

H. Lundbeck A/S ( CPH:HLUN B ) just reported healthy earnings but the stock price didn't move much. Our analysis...
Article d’analyse • Nov 15

Results: H. Lundbeck A/S Exceeded Expectations And The Consensus Has Updated Its Estimates

H. Lundbeck A/S ( CPH:HLUN B ) investors will be delighted, with the company turning in some strong numbers with its...
Article d’analyse • Oct 28

Fewer Investors Than Expected Jumping On H. Lundbeck A/S (CPH:HLUN B)

With a price-to-earnings (or "P/E") ratio of 13.2x H. Lundbeck A/S ( CPH:HLUN B ) may be sending bullish signals at the...
Mise à jour du récit • Sep 05

CNS Pipeline And Global Expansion Will Unlock Future Opportunities

With both future P/E and consensus revenue growth forecasts essentially unchanged, there has been no meaningful revision to H. Lundbeck's analyst price target, which remains at DKK48.18.
Article d’analyse • Aug 16

The H. Lundbeck A/S (CPH:HLUN B) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

CPSE:HLUN B 1 Year Share Price vs Fair Value Explore H. Lundbeck's Fair Values from the Community and select yours It's...
User avatar
Nouveau récit • Dec 04

Vyepti's Asian Triumph And Pipeline Advancements Ignite Strong Revenue Growth

Strong growth of strategic brands, especially Vyepti and Rexulti, is expected to drive substantial revenue increase in Asian and emerging markets.

Prévisions de croissance des bénéfices et des revenus

CPSE:HLUN B - Estimations futures des analystes et données financières antérieures (DKK Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202824,9604,6655,5926,03710
12/31/202725,7354,8076,2446,72811
12/31/202625,7044,7105,6166,24711
3/31/202625,5203,7304,8255,448N/A
12/31/202524,6303,1924,8635,481N/A
9/30/202524,0783,7772,7783,406N/A
6/30/202523,5213,4532,8513,409N/A
3/31/202522,9513,2572,4152,997N/A
12/31/202422,0043,1432,7613,326N/A
9/30/202421,4412,6874,9365,421N/A
6/30/202420,6712,5864,1284,609N/A
3/31/202420,1562,4164,1454,663N/A
12/31/202319,9122,2903,5794,080N/A
9/30/202319,6142,4673,5284,426N/A
6/30/202319,3812,4793,5234,457N/A
3/31/202318,9182,3843,2924,102N/A
12/31/202218,2461,9162,6993,519N/A
9/30/202217,6191,6032,0512,615N/A
6/30/202216,9131,2361,7442,313N/A
3/31/202216,3981,1091,3441,959N/A
12/31/202116,2991,3181,6602,272N/A
9/30/202116,5211,8732,4052,949N/A
6/30/202116,9711,9652,3792,912N/A
3/31/202117,3812,1103,2633,757N/A
12/31/202017,6721,5813,3593,837N/A
9/30/202017,8189042,7133,171N/A
6/30/202017,4901,2422,9103,354N/A
3/31/202017,3661,5071,5021,960N/A
12/31/201917,0362,313N/A2,609N/A
9/30/201916,8113,091N/A3,621N/A
6/30/201917,3093,395N/A3,462N/A
3/31/201917,7663,606N/A4,815N/A
12/31/201818,1173,907N/A5,981N/A
9/30/201818,3133,806N/A5,922N/A
6/30/201818,0283,627N/A6,197N/A
3/31/201817,6083,236N/A5,397N/A
12/31/201717,2342,624N/A4,045N/A
9/30/201717,0072,544N/A3,731N/A
6/30/201716,6071,988N/A3,551N/A
3/31/201716,0751,612N/A3,420N/A
12/31/201615,6341,211N/A3,126N/A
9/30/201615,202290N/A4,158N/A
6/30/201614,923-1,289N/A2,755N/A
3/31/201614,801-5,427N/A936N/A
12/31/201514,594-5,694N/A197N/A
9/30/201514,108-5,879N/A-1,330N/A
6/30/201513,625-4,615N/A-464N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Les bénéfices de HLUN B devraient diminuer au cours des 3 prochaines années ( -4.5% par an).

Bénéfices vs marché: Les bénéfices de HLUN B devraient diminuer au cours des 3 prochaines années ( -4.5% par an).

Croissance élevée des bénéfices: Les bénéfices de HLUN B devraient baisser au cours des trois prochaines années.

Chiffre d'affaires vs marché: Les revenus de HLUN B devraient diminuer au cours des 3 prochaines années ( -3.4% par an).

Croissance élevée des revenus: Les revenus de HLUN B devraient diminuer au cours des 3 prochaines années ( -3.4% par an).

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de HLUN B devrait être faible dans 3 ans ( 13.3 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/06/19 13:26
Cours de l'action en fin de journée2026/06/19 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

H. Lundbeck A/S est couverte par 33 analystes. 11 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Emily FieldBarclays
Charles PitmanBarclays
Rosie TurnerBarclays